Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF) (2010 - 2026)

Ani Pharmaceuticals has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $20.9 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 8.61% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.4 million (up 17.79% YoY) and the FY2025 annual result came in at $91.4 million, up 34.97% from the prior year.
• Depreciation & Amortization (CF) slipped to $20.9 million in Q1 2026 per ANIP's latest filing, from $22.6 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $23.3 million in Q2 2025 and troughed at $12.9 million in Q4 2022.
• A 5-year average of $17.4 million and a median of $15.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) soared 58.41% in 2025, then fell 8.61% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $12.9 million in 2022, then increased by 17.87% to $15.2 million in 2023, then jumped by 48.74% to $22.6 million in 2024, then gained by 0.06% to $22.6 million in 2025, then dropped by 7.49% to $20.9 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $20.9 million, $22.6 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.